The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Amivantamab treatment and intra-tumoral gene expression and immune cell changes in refractory metastatic colorectal cancer (mCRC): Whole transcriptome RNA-sequencing analysis from the OrigAMI-1 study.
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Agenus; Amgen (I); EMD Serono; Merck Serono; Merus; Pfizer; Revolution Medicines; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
Paul Oberstein
Consulting or Advisory Role - Boehringer Ingelheim; Ipsen; Janssen Oncology; Jazz Pharmaceuticals; Loxo/Lilly
Speakers' Bureau - Ipsen; Jazz Pharmaceuticals
Research Funding - Amal Therapeutics (Inst); Arcus Biosciences (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst)
Expert Testimony - Merck
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals; Trumvira
Consulting or Advisory Role - Agenus; Astellas Pharma; BeiGene; Bristol-Myers Squibb/Medarex; Galvanize Therapeutics; MBQ Pharma; Revolution Medicines; Taiho Pharmaceutical; Xilio Therapeutics
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre; Takeda Science Foundation
 
Dirk Arnold
Employment - Asklepios Kliniken
Honoraria - Amgen; AstraZeneca; Boston Scientific; Bristol-Myers Squibb; Eisai Europe; Gilead Sciences; GlaxoSmithKline; Ipsen; Janssen Oncology; Merck Serono; Merck Sharp and Dome; Pierre Fabre; Sanofi/Regeneron; Seagen; SERVIER; Sirtex Medical; Takeda; TERUMO; Viatris
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Serono; MSD Oncology
Research Funding - Oncolytics (Inst)
Travel, Accommodations, Expenses - Boston Scientific
(OPTIONAL) Uncompensated Relationships - Deputy Editor Clin Colorectal Cancer; ESMO; ESMO Open
 
Yong Sang Hong
No Relationships to Disclose
 
Myung Ah Lee
Other Relationship - Funding from Janssen for study drugs and clinical trial support
 
Harvey Yu-Li Su
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck Serono; MSD Oncology
Travel, Accommodations, Expenses - Merck KGaA
 
Sae-Won Han
Honoraria - IMBdx
Consulting or Advisory Role - AstraZeneca; Natera
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeyondBio (Inst); Cell Biotech (Inst); GC Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst); Turnstone Bio (Inst)
 
Rianka Bhattacharya
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Emrullah Yilmaz
Employment - Johnson & Johnson/Janssen
Consulting or Advisory Role - Astellas Pharma
 
Mahesh Daksh
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Mahadi Baig
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Sanjib Chowdhury
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Xuesong Lu
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Joshua Curtin
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Medha Kamat
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Michael Gormley
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Bharvin Patel
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Elena Elez
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; Janssen; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Roche; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Genentech (Inst); Gercor (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); Taiho Pharmaceutical (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi; Seagan; SERVIER; Takeda